報價延遲最少15分鐘:2026/09/05 18:20 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
17.32 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.44/0.06
|
|
企業價值
2.34B
|
| 資產負債 |
|
每股賬面淨值
4.38
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
120.25M
|
|
每股收益
0.06
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low backpain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform. |
